POEMS syndrome
Information
- Disease name
- POEMS syndrome
- Disease ID
- DOID:14039
- Description
- "A blood protein disease that is characterized by polyneuropathy, oranomegaly, endocrinopathy, monoclonal gammopathy, and skin changes, especially hyperpigmentation." [url:https\://rarediseases.info.nih.gov/diseases/7411/poems-syndrome]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02921893 | Active, not recruiting | Early Phase 1 | Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome | October 31, 2016 | October 31, 2024 |
| NCT04396496 | Completed | Phase 2 | Treatment of POEMS Syndrome With Daratumumab | September 22, 2020 | October 16, 2023 |
| NCT01639898 | Completed | Phase 2 | POEMS Syndrome Treatment With Lenalidomide | July 2012 | July 2018 |
| NCT01816620 | Completed | Phase 2 | Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome | March 2014 | April 2017 |
| NCT02193698 | Completed | Phase 2 | Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial | July 2014 | April 2016 |
| NCT06040567 | Recruiting | Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study | September 23, 2023 | December 31, 2026 | |
| NCT04561557 | Recruiting | Early Phase 1 | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | September 22, 2020 | May 31, 2027 |
| NCT05263817 | Recruiting | Early Phase 1 | A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis | October 8, 2021 | October 1, 2024 |
| NCT05476458 | Recruiting | To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope | August 15, 2022 | July 1, 2023 | |
| NCT00971685 | Unknown status | Phase 2 | The Treatment of Lenalidomide in Patients With POEMS Syndrome | July 2009 | July 2011 |
- Disase is a (Disease Ontology)
- DOID:620
- Cross Reference ID (Disease Ontology)
- GARD:7411
- Cross Reference ID (Disease Ontology)
- MESH:D016878
- Cross Reference ID (Disease Ontology)
- NCI:C80303
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:79268002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0085404
- OrphaNumber from OrphaNet (Orphanet)
- 2905
- MedGen concept unique identifier (MedGen Concept name)
- C0085404
- MedGen concept unique identifier (MedGen Concept name)
- CN203035
- MedGen unique identifier (MedGen Concept name)
- 39276
- MedGen unique identifier (MedGen Concept name)
- 799584
- MeSH unique ID (MeSH (Medical Subject Headings))
- D016878